Tag

Vaccine Production

All articles tagged with #vaccine production

health1 year ago

"Scientists Concerned Over Egg-Based Bird Flu Vaccine"

Scientists are concerned about the reliance on egg-based technology for producing bird flu vaccines, which is seen as outdated and inefficient for a potential 21st-century pandemic. Despite investments in alternative methods like cell-based and mRNA vaccines, the industry remains heavily dependent on egg-based production due to existing infrastructure and financial considerations. The current stockpiled vaccines are only partially effective, and there is an urgent need for more advanced and scalable solutions to combat potential flu pandemics.

health-vaccines1 year ago

"Global Strategies for Ramping Up H5N1 Bird Flu Vaccine Distribution"

Deciding when to start mass-producing H5N1 vaccine is a complex and high-stakes decision due to the limited capacity of flu vaccine production lines, potential financial costs for manufacturers, and the need to prioritize pandemic vaccine over seasonal flu vaccine. There is currently no formal process for making this decision, and it remains unclear who will be responsible for triggering the switch to pandemic vaccine production. Additionally, challenges exist in incorporating H5N1 vaccine into seasonal flu shots and in vaccinating dairy cattle, including cost, international trade implications, and the need for further research.

health1 year ago

"FDA Panel Recommends Streamlined Flu Vaccine Revision After COVID-19 Impact"

FDA experts have recommended changes to flu vaccines, suggesting that quadrivalent flu vaccines be converted into trivalent vaccines for the 2024–2025 season to only reflect currently circulating viral strains, potentially increasing vaccine supplies. The removal of the B/Yamagata lineage component from the vaccines could boost annual production capacity from ~500M doses of quadrivalent shots to 700M trivalent vaccines, with flu vaccine makers like GSK, Sanofi, CSL Limited, and AstraZeneca involved. Additionally, drugmakers such as Pfizer/BioNTech, Moderna, and Novavax are studying combined flu and COVID vaccines.

health2 years ago

The Uncertain Future of mRNA Vaccines in the Flu Shot Market

Pharmaceutical companies that developed mRNA vaccines for COVID-19 are now exploring the flu vaccine market, which relies on an outdated production process. The advantages of mRNA flu shots include the potential for more accurate strain selection, quicker production timelines, and improved effectiveness. Additionally, mRNA vaccines could address supply issues during flu pandemics. However, challenges include public acceptance of mRNA technology, potential side effects, high costs, and a crowded market. The jury is still out on the effectiveness of combination vaccines for flu, COVID-19, and RSV. Experts believe that the mRNA platform has the potential to revolutionize flu vaccines, but further research and regulatory approval are needed to develop vaccines with longer-lasting and broader protection.

health2 years ago

India faces Covid surge and vaccine demand as new symptoms and variants emerge.

India is experiencing a surge in Covid-19 cases due to a new variant called Arcturus, which is believed to be 1.2 times more infectious than the last major sub-variant. The variant has been found in 22 countries, including the UK and the US, and is particularly concerning due to limitations in genomic sequencing and tracking. Arcturus seems to exhibit unique symptoms in children, including conjunctivitis. India has resumed vaccine production to combat the surge in cases.